Horizon Pharma plc

Shareholder Securities Fraud Litigation

Rigrodsky & Long, P.A. Announces Commencement of an Investigation of Horizon Pharma plc for Possible Violations of Federal Securities Laws

Rigrodsky & Long, P.A. announces that it has commenced an investigation of Horizon Pharma plc (“Horizon” or the “Company”) for possible violations of the federal securities laws by the Company and certain of its officers and directors.

In an October 19, 2015 online article, “Drug Makers Sidestep Barriers on Pricing,” published by The New York Times, it was reported that various drug manufacturers, including Horizon, have used specialty pharmacies “to circumvent efforts of insurers and pharmacists to switch patients to generic components, or even to the over-the-counter versions.” According to the article, by convincing doctors to submit prescriptions to affiliated mail-order specialty pharmacies, Horizon was able to charge inflated prescription prices. The day after the publication of the article, on October 20, 2015, the price of Horizon Pharma dropped to a close of $15.26 per share from a close of $19.07 per share on the previous day.

If you purchased shares of Horizon and wish to discuss this investigation, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242, or by e-mail at

Attorney advertising.  Prior results do not guarantee a similar outcome.